Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Blinatumomab |
Trade Name | Blincyto |
Synonyms | anti-CD19/anti-CD3 recombinant bispecific|monoclonal antibody MT103|MEDI-538 |
Drug Descriptions |
Blincyto (blinatumomab) is a bispecific antibody that binds both CD19 on B-cells and the CD3 complex on T-cells, therefore facilitates T-cell mediated killing of CD19-expressing tumor cells (PMID: 26337639). Blincyto (blinatumomab) is FDA approved for the treatment of B-cell precursor acute lymphoblastic leukemia in adult and children negative for BCR-ABL1 (FDA.gov). |
DrugClasses | CD19 Antibody 19 |
CAS Registry Number | 853426-35-4 |
NCIT ID | C62528 |